N/A
Completed N=160
Acupuncture for Chemotherapy-Induced Nausea and Vomiting
Source: ClinicalTrials.gov NCT02195921 ↗Enrolled (actual)
160
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcomePrimary: Percentage of Participants With Nausea — 31; 47; 54; 53 percentage of participants
Summary
The purpose of this study is to clarify whether the matching acupoints is more effective than a single point by electroacupuncture in the management of chemotherapy-induced nausea and vomiting .
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Nausea |
31; 47; 54; 53 | — |
| PRIMARY Number of Times Vomiting Occurs After Chemotherapy |
0.44; 0.54; 0.78; 0.53 | — |
| PRIMARY Rhodes Index of Nausea, Vomiting and Retching |
— | — |
| PRIMARY Percentage of Participants With Nausea and Number of Times of Vomiting Occurs After Chemotherapy |
— | — |
| SECONDARY Grading of Constipation and Diarrhea |
— | — |
| SECONDARY Electrogastrogram |
— | — |
| SECONDARY the Assessment of Quality of Life |
47; 47; 45; 45 | — |
| SECONDARY the Assessment of Anxiety and Depression |
8; 7; 8; 7 | — |
Eligibility Criteria
Inclusion Criteria
- Be diagnosed as cancer and need to accept chemotherapy.
- The score of Karnofsky ≥70
- Patients of either gender and older than 18 years
- Patients receiving chemotherapy both outpatients and inpatients
- Patients receiving chemotherapy either he first or multiple cycle, but the patient will be taken in only one time
- To receive chemotherapy containing cisplatin(DDP≥75mg/m2) or joint chemotherapy programmes of Anthracyclines(Adriamycin≥40mg/m2 or epirubicin≥60mg/m2)
- Life expectancy≥ 6 months
- Willing to participate in the study and be randomized into one of the four study groups.
Exclusion Criteria
- To receive radiotherapy and chemotherapy
- Gastrointestinal tumors
- Patients with serious liver disease or abnormal hepatorenal function (AST,ACT, and TBIL are 3 times more than normal, BUN and Cr are 2 times more than normal)
- Presence of cardiac pacemaker
- Active skin infection
- Nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolyte disturbances)
- Patients unable to provide self-care or communication
- Nausea and/or vomiting resulting from mechanical risk factors (i.e., intestinal obstruction)
- Brain metastases
- Women in pregnant and lactating period
Data sourced from ClinicalTrials.gov (NCT02195921). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.